Canton Strategic Holdings (CNTN) Research & Development (2021 - 2026)
Canton Strategic Holdings posted quarterly Research & Development of $267823.0 for Q1 2026, down 54.92% year-on-year from $594070.0 in Q1 2025, and down 83.83% on a QoQ basis from $1.7 million in Q4 2025.
Canton Strategic Holdings (CNTN) has 6 years of Research & Development data on file, last reported at $267823.0 in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 54.92% year-over-year to $267823.0; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (down 53.9% YoY), and the FY2025 full-year result was $3.1 million, down 51.91% from the prior year.
- Research & Development for Q1 2026 stood at $267823.0, down from $1.7 million in the prior quarter.
- Across five years, Research & Development topped out at $2.3 million in Q3 2024 and bottomed at $267823.0 in Q1 2026.
- The 5-year median for Research & Development is $831844.0 (2022), against an average of $915996.6.
- The widest annual swing landed in 2022, when Research & Development soared 1766.15%; it then tumbled 87.83% in 2025.
- A 5-year view of Research & Development shows it stood at $683205.0 in 2022, then jumped by 45.3% to $992725.0 in 2023, then surged by 110.07% to $2.1 million in 2024, then fell by 20.6% to $1.7 million in 2025, then sank by 83.83% to $267823.0 in 2026.
- The last three Research & Development figures came in at $267823.0 (Q1 2026), $1.7 million (Q4 2025), and $277803.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | 267,823.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 267,823.00 |
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 277,803.00 |
| Jun 30, 2025 | 546,204.00 |
| Mar 31, 2025 | 594,070.00 |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 999,553.00 |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 992,725.00 |
| Sep 30, 2023 | 488,177.00 |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 683,205.00 |
| Sep 30, 2022 | 831,844.00 |
| Jun 30, 2022 | 455,546.00 |
| Mar 31, 2022 | 307,829.00 |
| Dec 31, 2021 | -41,005.00 |
| Sep 30, 2021 | 313,133.00 |
| Jun 30, 2021 | 674,765.00 |
| Mar 31, 2021 | 895,910.00 |